Original Research
Published on 23 Sep 2020
Simultaneous Combination of the CDK4/6 Inhibitor Palbociclib With Regorafenib Induces Enhanced Anti-tumor Effects in Hepatocarcinoma Cell Lines
in Cancer Molecular Targets and Therapeutics
- 6,562 views
- 23 citations